Ranbaxy reassurance
September 26, 2013
Ranbaxy Australia has
responded to the US Food and Drug
Administration import restrictions
on medications manufactured in
the company’s Mohali, India plant
(PD 20 Sep), this morning issuing
a statement confirming that the
Australian operation does not
currently source products from the
facility.
The FDA move was a response
to inspections revealing significant
GMP violations at the factory.
“As such, the ‘import alert’ placed
on the Mohali manufacturing plant
by the FDA will have no bearing on
the local business,” Ranbaxy said.
“Please be assured that Ranbaxy
remains fully committed to
upholding the highest standards
that patients, prescribers,
regulators and all other
stakeholders expect from the
Company and we stay firmly
committed to our policy of ‘Quality
and Patients First’,” the statement
concluded.
The above article was sent to subscribers in Pharmacy Daily's issue from 26 Sep 13To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 26 Sep 13
